Investors | EA Pharma Co., Ltd.

“LIVACT® Granules”－A Branched-chain Amino Acid Formula –Launches in Thailand | Investors（2018） | EA Pharma Co., Ltd.

Written by EAファーマ | Mar 9, 2018 2:29:00 AM

EA Pharma Co., Ltd.

EA Pharma Co., Ltd. (President & CEO, Yuji Matsue; Headquarters, Tokyo, Japan) (hereinafter“EA Pharma”), a subsidiary of Eisai Co., Ltd. for the gastrointestinal disease area, announced today that EA Pharma has launched “LIVACT® Granules” in Thailand.

“LIVACT® Granules” – a granular formula that contains branched-chain amino acids (L-isoleucine, L-leucine and L-valine) – is an ethical pharmaceutical product indicated for improvement of hypoalbuminemia in patients with decompensated liver cirrhosis who are suffering from hypoalbuminemia regardless of sufficient dietary intake.

Under a distributorship agreement with DKSH Group for the market of Thailand, EA Pharma collaborates with DKSH’s deployed dedicated marketing manager for EA Pharma’s products in DKSH’s local affiliate in the country. Taking advantage of the knowledge obtained in Japan, Vietnam, Myanmar and other countries where “LIVACT® Granules” has been marketed, EA Pharma will develop the marketing activity in Thailand.

EA Pharma expects that the knowledge obtained in Japan will be applicable to healthcare in other Asian countries because there are similarities in the food culture and people’s physical constitution between Japan and these counties. EA Pharma particularly focuses on East Asia and Southeast Asia, where there are high unmet medical needs, for expansion of its overseas business.

EA Pharma desires to make a contribution to increasing the quality of life of patients with decompensated liver cirrhosis in Thailand through the launch of “LIVACT® Granules” in the country.

End

More information
1. About LIVACT® Granules
“LIVACT® Granules” is a branched-chain amino acid granular formula that was developed by Ajinomoto Co., Inc. “LIVACT® Granules” was approved for marketing and launched in 1996 in Japan, indicated for improvement of hypoalbuminemia in patients with decompensated liver cirrhosis who are suffering from hypoalbuminemia regardless of sufficient dietary intake. In 2003, an additional approval to the partial change of dosage form of 25% reduced dose volume with the same content of active ingredients was obtained for the purpose of increasing patient adherence. In addition, in 2013, a new dosage form of oral jelly “LIVACT® Jelly” was launched for patients who hesitate to take granular medicine due to the uncomfortable texture when swallowing granules. “LIVACT® Granules” are marketed in Japan, Korea, Vietnam, Myanmar, Philippines, Hong Kong, Macao and Mongolia (The brand name for the Philippines is LIVAMIN®).
2. About EA Pharma Co., Ltd.

EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd. for gastrointestinal disease area, was established in April 2016 by integration of the gastrointestinal business unit with more than 60 years’ history of the Eisai Group and the gastrointestinal business unit of the Ajinomoto Group having amino acid as its business core. EA Pharma is a gastrointestinal specialty pharma with a full value chain covering R&D, logistics and sales & marketing.
For more information on EA Pharma Co., Ltd., please see http://www.eapharma.co.jp/en/

3. About DKSH Group.
DKSH Group is a leading company group that provides “Market Expansion Services” globally centered in Asia. In 37 countries over the world, DKSH Group has 825 offices with 31,970 experts achieving 11 billion sales in Swiss Franc in 2017.
DKSH Group shares have been listed on SIX Swiss Exchange since 2012.
The healthcare division of DKSH Group provides a wide range of solutions covering product registration, market research, marketing, sales, distribution, logistics and collection of receivables of prescription drugs, OTC and medical devices for those companies who want to expand their business in Asia.
View full post